-+ 0.00%
-+ 0.00%
-+ 0.00%

MiNK Therapeutics Q4 2024 GAAP EPS $(0.62) Misses $(0.50) Estimate

Benzinga·03/18/2025 11:37:40
Listen to the news
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.50) by 24 percent. This is a 287.5 percent decrease over losses of $(0.16) per share from the same period last year.